Antidepressants Global Market Report 2024 - By Trends, Report, Size, Share, Forecast To 2033

"The Business Research Company has updated its global market reports, featuring the latest data for 2024 and projections up to 2094

The Business Research Company presents an extensive market research report on the Antidepressants Global Market Report 2024, furnishing businesses with a competitive edge through a detailed examination of the market structure, encompassing estimates for various segments and sub-segments.

Furthermore, the report highlights on emerging trends, significant drivers, challenges, and opportunities, providing all necessary data for thriving in the industry. This report market research offers a comprehensive perspective, including an in-depth analysis of the present and future scenarios within the industry.

Market Sizing:
The antidepressants market size has grown steadily in recent years. It will grow from $16.6 billion in 2023 to $17.32 billion in 2024 at a compound annual growth rate (CAGR) of 4.3%. The growth in the historic period can be attributed to increasing prevalence of mental health disorders, growing awareness and reduced stigma, advancements in diagnostic practices, expansion of treatment options, government initiatives and mental health policies.

The antidepressants market size is expected to see steady growth in the next few years. It will grow to $19.88 billion in 2028 at a compound annual growth rate (CAGR) of 3.5%. The growth in the forecast period can be attributed to rising mental health awareness and advocacy, global impact of stress and lifestyle changes, integration of mental health services, research and development in psychiatry, telemedicine and remote mental health services. Major trends in the forecast period include regulatory changes, market competition, generic market growth, focus on side effect profiles, emerging markets.

Request for free sample report -
https://www.thebusinessresearchcompany.com/sample.aspx?id=2881&type=smp

Key Market Players:
Major companies operating in the antidepressants market report are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A., Bristol Myers Squibb Company, Fresenius Kabi AG, Abbott Laboratories, AstraZeneca plc, GlaxoSmithKline plc, Takeda Pharmaceutical Co. Ltd., Eli Lilly and Company, Boehringer Ingelheim GmbH, H. Lundbeck AS, Teva Pharmaceutical Industries Ltd., Akeda Pharmaceutical Co., Otsuka Pharmaceutical Co., Mylan N.V, Sun Pharmaceuticals Pvt. Ltd., Servier Laboratories, Sumitomo Dainippon Pharma Co., Aurobindo Pharma Limited, Dr. Reddy's Laboratories Ltd., Hikma Pharmaceuticals plc, Allergan plc, Alkermes plc, Egis Pharmaceuticals plc, Forest Laboratories Inc.

Market Drivers:
Globally, rising cases of mental health disorders are the key factor in the growth of the antidepressant drug industry, as many customers rely on these medications to counter depression, anxiety disorder, and other mental diseases. Antidepressant medications are used in conditions such as depression, OCD, childhood enuresis, major depressive disorder, severe anxiety disorder, bipolar disorder, post-traumatic stress disorder (PTSD), and social anxiety disorder. Globally, the percentage of people with depression varies from 2% to 6%, and the elderly are at greater risk of depression compared to other age groups. According to WHO, in 2023, about 280 million people globally suffered from depression. Therefore, rising cases of mental health disorders are expected to drive the growth of the antidepressant market.

Learn More About The Market Report -
https://www.thebusinessresearchcompany.com/report/antidepressant-global-market-report

The antidepressants market covered in this report is segmented -
1) By Product: Selective Serotonin Reuptake Inhibitor (SSRI), Serotonin-norepinephrine Reuptake Inhibitor (SNRI), Tricyclic Antidepressant (TCA), Monoamine Oxidase Inhibitor (MAOI)
2) By Drug Class: Monoamine Oxidase Inhibitors, Serotonin Antagonist And Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Tricyclic Antidepressants
3) By Depressive Disorder: Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder

The report answers the following questions:
What are the primary factors propelling the market during the projected period?
In which region is the most substantial growth expected?
Which trend will take center stage in the upcoming period?
Want To Know More About The Business Research Company?

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model"

The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

Global Market Model - World's Most Comprehensive Database
The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps.

This release was published on openPR.